HTHaruyoshi Tanaka

Haruyoshi Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haruyoshi Tanaka has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retrograde transhepatic approach to right anterior vessels in left hepatic trisectionectomy: technical tips and short-term outcomes

    by Shoji Kawakatsu, Takashi Mizuno, Shunsuke Onoe, Nobuyuki Watanabe, Mihoko Yamada, Masaki Sunagawa, Taisuke Baba, Masamichi Hayashi, Hideki Takami, Haruyoshi Tanaka, et al.

  • Open Access

    Pancreatoduodenectomy for Non-Ampullary Duodenal Cancers: An Analysis of Lymph Node Metastatic Patterns Using the National Clinical Database of Japan Cohort

    by Masamichi Hayashi, Hiroyuki Yamamoto, Suguru Yamada, Takahashi Arata, Haruyoshi Tanaka, Keisuke Kurimoto, Hideki Takami, Shingo Kanaji, Takeshi Naitoh, Hiroki Yamaue, et al.

    BackgroundNon-ampullary duodenal cancer is rare, and the optimal extent of lymphadenectomy remains unclear. Because lymphatic spread may depend on tumor location, large-scale mapping of nodal metastasis is needed to guide surgical decision-making.MethodsThis observational cohort study included 881 patients who underwent pancreatoduodenectomy for non-ampullary duodenal cancer in Japan between 2018 and 2021 and were registered in the National Clinical Database. Tumor location was assessed by conventional duodenal portion, pre-, peri-, and post-ampullary axial location, and circumferential location. Survival outcomes, perioperative outcomes, and station-specific lymph node metastatic ratios were analyzed.ResultsLymph node metastasis was observed mainly in tumors invading the muscularis propria or deeper. Node-positive disease and undifferentiated histology were associated with worse survival. Tumors on the pancreatic side showed higher metastatic ratios than tumors on the opposite side. Pre-ampullary tumors tended to have poorer outcomes and broader nodal spread, including stations around the stomach, hepatoduodenal ligament, superior mesenteric vessels, and para-aortic region. Post-ampullary tumors without pancreatic head nodal metastasis showed limited extra-pancreatic-head nodal involvement. Surgery-associated mortality was below 4.0%.ConclusionsLymph node metastasis in non-ampullary duodenal cancer depends on tumor depth and location. Pancreatoduodenectomy with lymphadenectomy may be particularly appropriate for pancreatic-side tumors and tumors with pancreatic head nodal involvement, whereas selected post-ampullary tumors without such involvement may require less extensive lymphadenectomy. These findings provide a basis for refining surgical indications and lymphadenectomy strategies.

  • Open Access

    Phase II trial of gemcitabine plus nab-paclitaxel–based chemoradiotherapy for locally advanced pancreatic cancer (NUPAT-05): Survival outcomes and feasibility of conversion surgery

    by Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, et al.

    Introduction: Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a phase I trial of CRT with gemcitabine plus nab-paclitaxel (GnP) and established the recommended dose. This single-arm, phase II study evaluated the safety and efficacy of CRT incorporating GnP in patients with LAPC.Methods: Patients with LAPC received the NUPAT-05 trial protocol treatment (UMIN000028116). Conversion surgery (CS) was considered for patients who achieved favorable local disease control and tumor marker normalization. The primary endpoint was the 2-year overall survival (OS) rate, with a predefined threshold of 15%, and the co-primary feasibility endpoint was the CS rate. The secondary endpoints included OS, progression free survival (PFS), time to treatment failure (TTF), and adverse events.Results: Twenty-five patients were enrolled in the trial. The 2-year OS rate was 36.0% (95% confidence interval [CI] = 18.0–57.5), meeting the primary endpoint. The CS rate was 32.0% (95% CI = 14.9–53.5). The 2-year OS rate reached 75.0% (95% CI = 31.5–93.1) among patients who underwent CS. The median OS, PFS, and TTF were 20.8, 13.8, and 7.9 months, respectively. Postoperative major complications occurred in 37.5% of patients undergoing CS. Although adverse events (grade ≥ 3) occurred in 92.0% of patients, no treatment-related grade 5 events occurred.Conclusions: GnP-based CRT displayed encouraging clinical activity with manageable toxicity in patients with LAPC. Future studies are needed to validate the additional benefits of radiotherapy.

  • Open Access

    Significance of Self‐Expandable Metallic Stent for Postoperative Intra‐Abdominal Infection After Pancreatoduodenectomy in Patients With a Hard Pancreas

    by Kosuke Mori, Haruyoshi Tanaka, Nana Kimura, Mina Fukasawa, Ayaka Itoh, Yoshihiro Shirai, Kazuto Shibuya, Kentaro Nagaoka, Yoshihiro Yamamoto, Tsutomu Fujii

    Background: Self‐expandable metal stents (SEMS) are often used for preoperative biliary drainage in pancreatoduodenectomy (PD); however, their impact on postoperative intra‐abdominal infection (POAI) remains unclear. This study aimed to evaluate the clinical significance of SEMS in relation to POAI. Methods: The data of 314 consecutive patients who underwent elective PD between January 2018 and May 2022 were retrospectively analyzed. Patients were categorized by biliary drainage method (NON: no preoperative biliary drainage, PS: plastic stent, or SEMS), and the associations with POAI were assessed. Bile and drainage fluid cultures were microbiologically examined. Results: Soft pancreatic texture and preoperative biliary drainage were independently associated with POAI. In the hard pancreas subgroup undergoing preoperative biliary drainage ( n = 45), all POAI cases occurred despite low drain fluid amylase levels and the absence of clinically relevant postoperative pancreatic fistula (POPF). SEMS placement was the only significant risk factor for POAI (odds ratio 4.38 [1.21–18.73], p = 0.03). The concordance rate between organisms in bile and drainage fluid was 66.7% in the SEMS group, 52.2% in the PS group, and 7.2% in the NON group. In the SEMS group, E. cloacae , E. faecalis , and E. faecium were the most frequently isolated organisms (38.1%, 33.3%, and 19.0%, respectively). Conclusion: SEMS placement was associated with an increased risk of POAI in patients with a hard pancreas, who are unlikely to develop POPF. Bile cultures may assist in predicting the causative organisms of POAI in patients who undergo preoperative biliary drainage.

  • Open Access

    A novel melting temperature mapping method may improve the prediction of postoperative intra-abdominal infection after pancreatoduodenectomy

    by Haruyoshi Tanaka, Mina Fukasawa, Nana Kimura, Kosuke Mori, Koshi Matsui, Ayaka Itoh, Katsuhisa Hirano, Toru Watanabe, Yoshihiro Shirai, Kentaro Nagaoka, et al.


  • Open Access

    FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (GEMINI-PC-01)

    by Haruyoshi Tanaka, Ayano Sakai, Masaya Suenaga, Masamichi Hayashi, Tomohisa Otsu, Nobuhiko Nakagawa, Keisuke Kurimoto, Mina Fukasawa, Kazuto Shibuya, Nobuyuki Watanabe, et al.


  • Open Access

    Novel choledochojejunostomy technique “T‐shaped anastomosis” for preventing the development of postoperative cholangitis in pancreatoduodenectomy: A propensity score matching analysis

    by Nana Kimura, Takamichi Igarashi, Kenta Murotani, Ayaka Itoh, Toru Watanabe, Katsuhisa Hirano, Haruyoshi Tanaka, Kazuto Shibuya, Isaku Yoshioka, Tsutomu Fujii

    Background: There have been few studies of countermeasures against postoperative cholangitis, a serious complication after pancreaticoduodenectomy (PD) that impairs quality of life.Objective: To evaluate our recently developed, novel method of choledochojejunostomy with a larger anastomotic diameter, the “T‐shaped anastomosis.”Methods: The study included 261 cases of PD. The T‐shaped choledochojejunostomy technique was performed with an additional incision for a distance greater than half the diameter of the bile duct at the anterior wall of the bile duct and the anterior wall of the elevated jejunum. To compensate for potential confounding biases between the standard anastomosis group (n = 206) and the T‐shaped anastomosis group (n = 55), we performed propensity score matching (PSM). The primary endpoint was the incidence of medium‐term postoperative cholangitis adjusted for PSM.Results: In the PSM analysis, 54 patients in each group were matched, and the median bile duct diameter measured by preoperative CT was 8.8 mm versus 9.3 mm, the rate of preoperative biliary drainage was 31% versus 37%, the incidence of cholangitis within 1 month before surgery was 9% versus 13%, and the incidence of postoperative bile leakage was 2% versus 2%, with no significant differences. The incidence of medium‐term postoperative cholangitis was 15% versus 4%, and multivariate logistic regression revealed that T‐shaped choledochojejunostomy was an independent predictor of a reduced incidence of cholangitis (odds ratio, 0.17, 95% CI 0.02–0.81; p = 0.024).Conclusions: The T‐shaped choledochojejunostomy technique was shown to be effective with a significant reduction in the incidence of medium‐term postoperative cholangitis. Clinical trial identification: UMIN000050990.


  • Open Access

    Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology

    by Mina Fukasawa, Toru Watanabe, Haruyoshi Tanaka, Ayaka Itoh, Nana Kimura, Kazuto Shibuya, Isaku Yoshioka, Kenta Murotani, Kenichi Hirabayashi, Tsutomu Fujii

    Background: The frequency and prognosis of positive peritoneal washing cytology (CY1) in resectable pancreatic ductal adenocarcinoma (R‐PDAC) remains unclear. The objective of this study was to identify the clinical implications of CY1 in R‐PDAC and staging laparoscopy (SL).Methods: We retrospectively analyzed 115 consecutive patients with R‐PDAC who underwent SL between 2018 and 2022. Patients with negative cytology (CY0) received radical surgery after neoadjuvant chemotherapy, while CY1 patients received systemic chemotherapy and were continuously evaluated for cytology.Results: Of the 115 patients, 84 had no distant metastatic factors, 22 had only CY1, and nine had distant metastasis. Multivariate logistic regression revealed that larger tumor size was an independent predictor of the presence of any distant metastatic factor (OR: 6.30, p = .002). Patients with CY1 showed a significantly better prognosis than patients with distant metastasis (MST: 24.6 vs. 18.9 months, p = .040). A total of 11 CY1 patients were successfully converted to CY‐negative, and seven underwent conversion surgery. There was no significant difference in overall survival between patients with CY0 and those converted to CY‐negative.Conclusion: SL is effective even for R‐PDAC. The prognosis of CY1 patients converted to CY‐negative is expected to be similar to that of CY0 patients.


  • Open Access

    Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology

    by Takamichi Igarashi, Mina Fukasawa, Toru Watanabe, Nana Kimura, Ayaka Itoh, Haruyoshi Tanaka, Kazuto Shibuya, Isaku Yoshioka, Kenichi Hirabayashi, Tsutomu Fujii

    Introduction: The prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of staging laparoscopy (SL) and treatment efficacy in CY1 patients based on a resectability classification.Methods: We retrospectively reviewed 250 patients with PDAC who underwent SL before the initial treatment between 2017 and 2023 at the University of Toyama.Results: The breakdown of cases by resectability classification was resectable (R):borderline resectable (BR):unresectable locally advanced (UR‐LA) = 131:48:71 cases. The frequency of CY1 increased in proportion to the degree of local progression (R:BR:UR‐LA = 20:23:34%), but the frequencies of liver metastasis or peritoneal dissemination were comparable (R:BR:UR‐LA = 6.9:6.3:8.5%). Most CY1 patients received gemcitabine along with nab‐paclitaxel therapy. The CY‐negative conversion rates (R:BR:UR‐LA = 70:64:52%) and conversion surgery rates (R:BR:UR‐LA = 40:27:9%) were inversely proportional to the degree of local progression.Comparing H0P0CY1 factors for each classification, patients with H0P0CY1 had significantly more pancreatic body or tail carcinoma and tumor size ≥32 mm in R patients, whereas in BR patients, duke pancreatic monoclonal antigen type 2 (DUPAN‐2) ≥ 230 U/mL was a significant factor. In contrast, no significant factors were observed in UR‐LA patients.Conclusion: The CY1 rates, CY‐negative conversion rates, and conversion surgery rates varied according to local progression. In the case of R and BR, SL could be considered in patients with pancreatic body or tail carcinoma, large tumor size, or high DUPAN‐2 level. In UR‐LA, SL might be considered for all patients.